Alemtuzumab for refractory celiac disease in a patient at risk for enteropathy-associated T-cell lymphoma.
Vivas
Santiago
S
Ruiz de Morales
José María
JM
Ramos
Fernando
F
Suárez-Vilela
Dimas
D
D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002446:Celiac Disease / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D004379:Duodenal Neoplasms / Q000517:prevention & control; D004386:Duodenum / Q000473:pathology*; D005260:Female; D006801:Humans; D016399:Lymphoma, T-Cell / Q000517:prevention & control*; D008875:Middle Aged
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000074323:Alemtuzumab